Literature DB >> 1983828

Insulin resistance in noncirrhotic idiopathic portal hypertension.

A S Petrides1, C A Riely, R A DeFronzo.   

Abstract

To explore further the pathogenesis of glucose intolerance and insulin resistance observed in patients with cirrhosis and portal hypertension, we studied a 35-year-old woman with presinusoidal portal hypertension without cirrhosis due to nodular regenerative hyperplasia of the liver. After oral glucose ingestion, glucose tolerance remained normal; however, this occurred at the expense of a markedly hyperinsulinemic plasma response, suggesting the presence of insulin resistance. To examine this question more directly, we performed a stepwise euglycemic insulin clamp study in combination with an infusion of [6-3H]glucose and [1-14C]palmitate and indirect calorimetry. The ability of insulin to promote total body (primarily muscle) glucose uptake was markedly impaired, whereas its effect to suppress hepatic glucose production was normal compared with results obtained in nine healthy subjects. Moreover, insulin failed to normally suppress plasma free fatty acid turnover and oxidation in this patient. This informative case demonstrates that portal hypertension alone, without hepatic dysfunction from cirrhosis, is associated with impaired insulin-mediated glucose and plasma free fatty acid metabolism and may also play a predominant role in the development of insulin resistance in many cirrhotic patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1983828     DOI: 10.1016/0016-5085(91)90608-n

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  2 in total

Review 1.  Metabolism of energy-yielding substrates in patients with liver cirrhosis.

Authors:  M J Müller; K H Böker; O Selberg
Journal:  Clin Investig       Date:  1994-08

2.  Incidence of insulin resistance and diabetes in patients with portosystemic shunts without liver dysfunction.

Authors:  Ying Li; Gao Yang; Jinwei Qiang; Songqi Cai; Hao Zhou
Journal:  J Int Med Res       Date:  2016-09-29       Impact factor: 1.671

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.